The role of CDK5/P25 formation/inhibition in neurodegeneration

Drug News and Perspectives

Volumn 19, Issue 8, 2006, Pages 453-460

  Camins, Antoni ^a   Verdaguer, Ester ^b   Folch, Jaume ^c   Canudas, Anna Maria ^a   Pallàs, Mercè ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b Servei Farmacologia Clínica   (Spain)

^c UNIVERSITAT ROVIRA I VIRGILI   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; CALPASTATIN; CYCLIN DEPENDENT KINASE 5; FLAVOPIRIDOL; GLYCOGEN SYNTHASE KINASE 3BETA; INDURIBIN DERIVATIVE; KENPAULLONE; MYOCYTE ENHANCER FACTOR 2; PRALIDOXIME MESILATE; PROTEIN C JUN; PROTEIN P35; PROTEIN P39; RETINOBLASTOMA PROTEIN; ROSCOVITINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; BRAIN DEVELOPMENT; CELL DEATH; HUMAN; HUNTINGTON CHOREA; MUTATION; NERVE DEGENERATION; NEUROLOGIC DISEASE; NEUROTOXICITY; NIEMANN PICK DISEASE; NONHUMAN; PARKINSON DISEASE; PROGRESSIVE SUPRANUCLEAR PALSY; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVIEW;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; APOPTOSIS; CYCLIN-DEPENDENT KINASE 5; HUMANS; HUNTINGTON DISEASE; NERVE TISSUE PROTEINS; NEURODEGENERATIVE DISEASES; NEURONS; NEUROPROTECTIVE AGENTS; NIEMANN-PICK DISEASE, TYPE C; PARKINSON DISEASE; PROTEIN KINASE INHIBITORS; SUPRANUCLEAR PALSY, PROGRESSIVE;

EID: 33846030132     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2006.19.8.1043961     Document Type: Review

References (67)

1. Heintz, N. Cell death and the cell cycle: A relationship between transformation and neurodegeneration? Trends Biochem Sci 1993, 18: 157-9.
2. Neve, R.L. and McPhie, D.L. The cell cycle as a therapeutic target for Alzheimer's disease. Pharmacol Ther 2006, 111: 99-113.
3. Becker, E.B. and Bonni, A. Beyond proliferation-cell cycle control of neuronal survival and differentiation in the developing mammalian brain. Semin Cell Dev Biol 2005, 16: 439-48.
4. Becker, E.B. and Bonni, A. Cell cycle regulation of neuronal apoptosis in development and disease. Prog Neurobiol 2004, 72: 1-25.
5. Patrick, G.N., Zukerberg, L., Nikolic, M. et al. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 1999, 402: 615-22.
6. Lee, M.S., Kwon, Y.T., Li, M. et al. Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature 2000, 405: 360-4.
7. Bian, F., Nath, R., Sobocinski, G. et al. Axonopathy, tau abnormalities, and dyskinesia, but no neurofibrillary tangles in p25-transgenic mice. J Comp Neurol 2002, 446: 257-66.
8. Gupta, A., Sanada, K., Miyamoto, D.T. et al. Layering defect in p35 deficiency is linked to improper neuronal-glial interaction in radial migration. Nat Neurosci 2003, 6: 1284-91.
9. Fischer, A., Sananbenesi, F., Pang, P.T. et al. Opposing roles of transient and prolonged expression of p25 in synaptic plasticity and hippocampus-dependent memory. Neuron 2005, 48: 825-38.
10. Cheung, Z.H. and Ip, N.Y. Cdk5: Mediator of neuronal death and survival. Neurosci Lett 2004, 361: 47-51.
11. Cruz, J.C., Tseng, H.C., Goldman, J.A. et al. Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles. Neuron 2003, 40: 471-83.
12. Noble, W., Olm, V., Takata, K. et al. Cdk5 is a key factor in tau aggregation and tangle formation in vivo. Neuron 2003, 38: 555-65.
13. Alvira, D., Tajes, M., Verdaguer, E. et al. Inhibition of the cdk5/p25 fragment formation may explain the antiapoptotic effects of nielatonin in an experimental model of Parkinson's disease. J Pineal Res 2006, 40: 251-8.
14. Alvarez, A., Toro, R., Caceres, A. et al. Inhibition of tau phosphorylating protein kinase cdk5 prevents beta-amyloid-induced neuronal death. FEES Lett 1999, 459: 421-6.
15. Bizat, N., Hermel, J.M., Boyer, F. et al. Calpain is a major cell death effector in selective striatal degeneration induced in vivo by 3-nitropropionate: Implications for Huntington's disease. J Neurosci 2003, 23: 5020-30.
16. O'Hare, M.J., Kushwaha, N., Zhang, Y. et al. Differential roles of nuclear and cytoplasmic cyclin-dependent kinase 5 in apoptotic and excitotoxic neuronal death. J Neurosci 2005, 25: 8954-66.
17. Gong, X., Tang, X., Wiedmann, M. et al. Cdk5-mediated inhibition of the protective effects of transcription factor MEF2 in neurotoxicity-induced apoptosis. Neuron 2003, 38: 33-46.
18. Smith, P.D., Mount, M.P., Shree, R. et al. Calpain-regulated p35/cdk5 plays a central role in dopaminergic neuron death through modulation of the transcription factor myocyte enhancer factor 2. J Neurosci 2006, 26: 440-7.
19. Verdaguer, E., Alvira, D., Jimenez, A. et al. Inhibition of the cdk5/MEF2 pathway is involved in the antiapoptotic properties of calpain inhibitors in cerebellar neurons. Br J Pharmacol 2005, 145: 1103-11.
20. Zhang, J., Krishnamurthy, P.K. and Johnson, G.V. Cdk5 phosphorylates p53 and regulates its activity. J Neurochem 2002, 81: 307-13.
21. Hamdane, M., Bretteville, A., Sambo, A.V. et al. 2005. p25/Cdk5 mediated retinoblastoma phosphorylation is an early event in neuronal cell death. J Cell Science 2005, 118: 1291-8.
22. Morfini, G., Szebenyi, G., Brown, H. et al. A novel CDK5-dependent pathway for regulating GSK3 activity and kinesin-driven motility in neurons. EMBO J 2004, 23: 2235-45.
23. Li, B.S., Zhang, L., Takahashi, S. et al. Cyclin-dependent kinase 5 prevents neuronal apoptosis by negative regulation of c-Jun N-terminal kinase 3. EMBO J 2002, 21: 324-33.
24. Otth, C., Mendoza-Naranjo, A., Mujica, L. et al. Modulation of the JNK and p38 pathways by cdk5 protein kinase in a transgenic mouse model of Alzheimer's disease. Neuroreport 2003, 14: 2403-9.
25. Zambrano, C.A., Egana, J.T., Nunez, M.T. et al. Oxidative stress promotes tau dephosphorylation in neuronal cells: The roles of cdk5 and PP1. Free Radic Biol Med 2004, 36: 1393-402.
26. Jacobsen, J.S., Reinhart, P. and Pangalos, M.N. Current concepts in therapeutic strategies targeting cognitive decline and disease modification in Alzheimer's disease. NeuroRx 2005, 2: 612-26.
27. Moreira, P.I., Zhu, X., Lee, H.G. et al. The (un)balance between metabolic and oxidative abnormalities and cellular compensatory responses in Alzheimer disease. Mech Ageing Dev 2006, 127: 501-6.
28. Baumann, K., Mandelkow, E.M., Biernat, J. et al. Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases cdk2 and cdk5. FEBS Lett 1993, 336: 417-24.
29. Liu, W.K., Williams, R.T., Hall, F.L. et al. Detection of a Cdc2-related kinase associated with Alzheimer paired helical filaments. Am J Pathol 1995, 146: 228-38.
30. Quintanilla, R.A., Orellana, D.I., Gonzalez-Billault, C. et al. Interleukin-6 induces Alzheimer-type phosphorylation of tau protein by deregulating the cdk5/p35 pathway. Exp Cell Res 2004, 295: 245-57.
31. Canudas, A.M., Gutierrez-Cuesta, J., Rodríguez, M.I. et al. Hyperphosphorylation of microtubule-associated protein tau in senescence-accelerated mouse (SAM). Mech Ageing Dev 2005, 126: 1300-4.
32. Liu, T., Perry, G., Chan, H.W. et al. Amyloid-beta-induced toxicity of primary neurons is dependent upon differentiation-associated increases in tau and cyclin-dependent kinase 5 expression. J Neurochem 2004, 88: 554-63.
33. Li, G., Faibushevich, A., Turunen, B.J. et al. Stabilization of the cyclin-dependent kinase 5 activator, p35, by paclitaxel decreases beta-amyloid toxicity in cortical neurons. J Neurochem 2003, 84: 347-62.
34. Zheng, Y.L., Kesavapany, S., Gravell, M. et al. A Cdk5 inhibitory peptide reduces tau hyperphosphorylation and apoptosis in neurons. EMBO J 2005, 24: 209-20.
35. Boland, B. and Campbell, V. beta-Amyloid (1-40)-induced apoptosis of cultured cortical neurones involves calpain-mediated cleavage of poly-ADP-ribose polymerase. Neurobiol Aging 2003, 24: 179-86.
36. Battaglia, F., Trinchese, F., Liu, S. et al. Calpain inhibitors, a treatment for Alzheimer's disease: position paper. J Mol Neurosci 2003, 20: 357-62.
37. Nakamura, S., Kawamoto, Y., Nakano, S. et al. p35nck5a and cyclin-dependent kinase 5 colocalize in Lewy bodies of brains with Parkinson's disease. Acta Neuropathol (Berl) 1997, 94: 153-7.
38. Brion, J.P. and Couck, A.M. Cortical and brainstem-type Lewy bodies are immunoreactive for the cyclin-dependent kinase 5. Am J Pathol 1995, 147: 1465-76.
39. Gonzalez-Polo, R.A., Soler, G. and Fuentes, J.M. MPP+: Mechanism for its toxicity in cerebellar granule cells. Mol Neurobiol 2004, 30: 253-64.
40. Mouatt-Prigent, A., Karlsson, J.O., Agid, Y. et al. Increased M-calpain expression in the mesencephalon of patients with Parkinson's disease but not in other neurodegenerative disorders involving the mesencephalon: A role in nerve cell death? Neuroscience 1996, 73: 979-87.
41. Crocker, S.J., Smith, P.D., Jackson-Lewis, V. et al. Inhibition of calpains prevents neuronal and behavioral deficits in an MPTP mouse model of Parkinson's disease. J Neurosci 2003, 23: 4081-91.
42. Smith, P.D., Crocker, S.J., Jackson-Lewis, V. et al. Cyclin-dependent kinase 5 is a mediator of dopaminergic neuron loss in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A 2003, 100: 13650-5.
43. Smith, P.D., O'Hare, M.J. and Park, D.S. CDKs: Taking on a role as mediators of dopaminergic loss in Parkinson's disease. Trends Mol Med 2004, 10: 445-51.
44. Smith, P.D., Mount, M.P., Shree, R. et al. Calpain regulated p35/cdk5 plays a central role in dopaminergic neuron death through modulation of the transcription factor myocyte enhancer factor 2. J Neurosci 2006, 26: 440-7.
45. Nguyen, M.D., Boudreau, M., Kriz, J. et al. Cell cycle regulators in the neuronal death pathway of amyotrophic lateral sclerosis caused by mutant superoxide dismutase 1. J Neurosci 2003, 23: 2131-40.
46. Patzke, H. and Tsai, L.H. Cdk5 sinks into ALS. Trends Neurosci 2002, 25: 8-10.
47. Nguyen, M.D., Lariviere, R.C. and Julián, J.P. Deregulation of Cdk5 in a mouse model of ALS: toxicity alleviated by perikaryal neurofilament inclusions. Neuron 2001, 30: 135-47.
48. Bajaj, N.P., al Sarraj, S.T., Leigh, P.N. et al. Cyclin dependent kinase-5 (CDK-5) phosphorylates neurofilament heavy (NF-H) chain to generate epitopes for antibodies that label neurofilament accumulations in amyotrophic lateral sclerosis (ALS) and is present in affected motor neuronas in ALS. Prog Neuropsychopharmacol Biol Psychiatry 1999, 23: 833-50.
49. Bajaj, N.P., Al Sarraj, S.T., Anderson, V. et al. Cyclin-dependent kinase-5 is associated with lipofuscin in motor neurones in amyotrophic lateral sclerosis. Neurosci Lett 1998, 245: 45-8.
50. Nakamura, S., Kawamoto, Y., Nakano, S. et al. Cyclin-dependent kinase 5 in Lewy body-like inclusions in anterior horn cells of a patient with sporadic amyotrophic lateral sclerosis. Neurology 1997, 48: 267-70.
51. Bu, B., Li, J., Davies, P. et al. Deregulation of cdk5, hyperphosphorylation, and cytoskeletal pathology in the Niemann-Pick type C murine model. J Neurosci 2002, 22: 6515-625.
52. Sawamura, N., Gong, J.S., Garver, W.S. et al. Site-specific phosphorylation of tau accompanied by activation of mitogen-activated protein kinase (MAPK) in brains of Niemann-Pick type C mice. J Biol Chem 2001, 276: 10314-9.
53. Zhang, M., Li, J., Chakrabarty, P. et al. Cyclin-dependent kinase inhibitors attenuate protein hyperphosphorylation, cytoskeletal lesion formation, and motor defects in Niemann-Pick Type C mice. Am J Pathol 2004, 165: 843-53.
54. Rashidian, J., Iyirhiaro, G., Aleyasin, H. et al. Multiple cyclin-dependent kinases signals are critical mediators of ischemia/ hypoxic neuronal death in vitro and in vivo. Proc Natl Acad Sci U S A 2005, 102: 14080-5.
55. Hayashi, T., Warita, H. and Abe, K. Expression of cyclin-dependent kinase 5 and its activator p35 in rat brain after middle cerebral artery occlusion. Neurosci Lett 1999, 265: 37-40.
56. Green, S.L., Kulp, K.S. and Vulliet, R. Cyclin-dependent protein kinase 5 activity increases in rat brain following ischemia. Neurochem Int 1997, 31: 617-23.
57. Wu Chen, R., Zhang, Y., Rose, M.E. et al. Cyclooxygenase-2 activity contributes to neuronal expression of cyclin D1 after anoxia/ischemia in vitro and in vivo. Brain Res Mol Brain Res 2004, 132: 31-7.
58. Wang, F., Corbett, D., Osuga, H. et al. Inhibition of cyclin-dependent kinases improves CA1 neuronal survival and behavioral performance after global ischemia in the rat. J Cereb Blood Flow Metab 2002, 22: 171-82.
59. Osuga, H., Osuga, S., Wang, F. et al. Cyclin-dependent kinases as a therapeutic target for stroke. Proc Natl Acad Sci U S A 2000, 97: 10254-9.
60. Borghi, R., Giliberto, L., Assini, A. et al. Increase of cdk5 is related to neurofibrillary pathology in progressive supranuclear palsy. Neurology 2002, 58: 589-92.
61. Chen, P.C. and Chen, J.C. Enhanced Cdk5 activity and p35 translocation in the ventral striatum of acute and chronic methamphetamine-treated rats. Neuropsychopharmacology 2005, 30: 538-19.
62. Park, D.S., Obeidat, A., Giovanni, A. and Greene, L.A. Cell cycle regulators in neuronal death evoked by excitotoxic stress: Implications for neurodegeneration and its treatment. Neurobiol Aging 2000, 21: 771-81.
63. Jorda, E.G., Verdaguer, E. and Canudas, A.M., Neuroprotective action of flavopiridol, a cyclin-dependent kinase inhibitor, in colchicine-induced apoptosis. Neuropharmacology 2003, 45: 672-83.
64. Zapata-Torres, G., Opazo, F., Salgado, C. et al. Effects of natural flavones and flavonols on the kinase activity of Cdk5. J Nat Prod 2004, 67: 416-20.
65. Di Giovanni, S., Movsesyan, V., Ahmed, F. et al. Cell cycle inhibition provides neuroprotection and reduces glial proliferation and scar formation after traumatic brain injury. Proc Natl Acad Sci U S A 2005, 102: 8333-8.
66. Cernak, I., Stoica, B., Byrnes, K.R. et al. Role of the cell cycle in the pathobiology of central nervous system trauma. Cell Cycle 2005, 4: 1286-93.
67. Leclerc, S., Garnier, M., Hoessel, R. et al. Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors? J Biol Chem 2001, 276: 251-60.